133 related articles for article (PubMed ID: 10508713)
1. Optimism after much pessimism: what next?
Milstein C; Waldmann H
Curr Opin Immunol; 1999 Oct; 11(5):589-91. PubMed ID: 10508713
[No Abstract] [Full Text] [Related]
2. Next-generation monoclonals less profitable than trailblazers?
Mitchell P
Nat Biotechnol; 2005 Aug; 23(8):906. PubMed ID: 16082347
[No Abstract] [Full Text] [Related]
3. Monoclonal antibodies in cancer therapy: 25 years of progress.
Oldham RK; Dillman RO
J Clin Oncol; 2008 Apr; 26(11):1774-7. PubMed ID: 18398141
[No Abstract] [Full Text] [Related]
4. Deal watch: Bristol-Myers Squibb invests in cancer antibody that targets the innate immune system.
Nat Rev Drug Discov; 2011 Aug; 10(9):648. PubMed ID: 21878969
[No Abstract] [Full Text] [Related]
5. GlaxoSmithKline cancer drug threatens Herceptin market.
Waltz E
Nat Biotechnol; 2005 Dec; 23(12):1453-4. PubMed ID: 16333273
[No Abstract] [Full Text] [Related]
6. Alemtuzumab.
Am J Health Syst Pharm; 2001 Dec; 58(24):2372-3. PubMed ID: 11794950
[No Abstract] [Full Text] [Related]
7. Targeted immunotherapies overtaking emerging oncology market value based growth.
Jakovljevic MB
J BUON; 2015; 20(1):350-1. PubMed ID: 25778340
[No Abstract] [Full Text] [Related]
8. FDA increases focus on postmarketing studies.
Goozner M
J Natl Cancer Inst; 2010 Sep; 102(17):1302-4. PubMed ID: 20739650
[No Abstract] [Full Text] [Related]
9. Tumor immunology top 10 list.
Finn OJ
Immunol Rev; 2008 Apr; 222():5-8. PubMed ID: 18363991
[No Abstract] [Full Text] [Related]
10. Promising drug is victim of bad business.
Dove A
Nat Med; 2002 Mar; 8(3):199. PubMed ID: 11875472
[No Abstract] [Full Text] [Related]
11. Deal watch: Genentech dives deeper into the next wave of cancer immunotherapies.
Crunkhorn S
Nat Rev Drug Discov; 2014 Dec; 13(12):879. PubMed ID: 25435209
[No Abstract] [Full Text] [Related]
12. PHARMAC responds on Herceptin assumptions and decisions.
Metcalfe S; Evans J
N Z Med J; 2007 Aug; 120(1260):U2692. PubMed ID: 17726504
[No Abstract] [Full Text] [Related]
13. BIO 2006 Annual International Convention. Innovations in biotech in China and Italy.
Tear S; Zarkowska T
IDrugs; 2006 Jun; 9(6):386-9. PubMed ID: 16752303
[No Abstract] [Full Text] [Related]
14. A target for tumour-directed therapy.
Hynes NE; Groner B
Nat Med; 1995 Jul; 1(7):631. PubMed ID: 7585140
[No Abstract] [Full Text] [Related]
15. Mixed news for Avastin.
Mack GS
Nat Biotechnol; 2009 Jun; 27(6):494. PubMed ID: 19513035
[No Abstract] [Full Text] [Related]
16. [Prospects for improving antibody therapy for carcinoma].
Liu XY
Zhonghua Yi Xue Za Zhi; 2004 Jul; 84(14):1145-6. PubMed ID: 15387972
[No Abstract] [Full Text] [Related]
17. Targeting of monoclonal antibodies to tumours.
Courtenay-Luck NS; Epenetos AA
Curr Opin Immunol; 1989-1990; 2(6):880-3. PubMed ID: 2486568
[No Abstract] [Full Text] [Related]
18. Immuno-oncology moves beyond PD-1.
Sheridan C
Nat Biotechnol; 2015 Jul; 33(7):673-5. PubMed ID: 26153987
[No Abstract] [Full Text] [Related]
19. Next steps for cancer immune therapy.
Cancer Discov; 2015 Mar; 5(3):221-2. PubMed ID: 25710919
[No Abstract] [Full Text] [Related]
20. Recent developments in humanized MAbs for immunotherapy: a personal tribute to Dr. Martin Lockwood.
Hale G
Transfus Sci; 1999 Dec; 21(3):181-4. PubMed ID: 10848438
[No Abstract] [Full Text] [Related]
[Next] [New Search]
